CRISPR and Genetic Engineering: What Every Parent of a Science-Curious Kid Needs to Understand

In November 2018, a Chinese researcher named He Jiankui announced at a scientific conference in Hong Kong that he had created the world’s first gene-edited human babies. He had used CRISPR to modify embryos that were then implanted and carried to term — twin girls, reportedly resistant to HIV infection. The scientific community’s reaction was not celebration. It was near-universal condemnation. He Jiankui was subsequently sentenced to three years in prison by a Chinese court. The experiment was described by the National Academies of Sciences, Engineering, and Medicine as “irresponsible” and “a serious breach of ethical norms.”

Five years later, in December 2023, the FDA approved Casgevy — the first CRISPR-based therapy — for sickle cell disease and beta-thalassemia. The same underlying molecular machinery. Completely different ethical territory. Casgevy treats cells taken from a patient’s body, edits them outside the body, and returns them. No heritable changes. No embryos. Rigorous clinical trials. Regulatory review.

Both of these stories are about CRISPR. Understanding why one is a landmark achievement and the other is a cautionary tale requires understanding how the technology actually works — and where scientists have drawn the ethical lines, and why. Your science-curious kid is going to encounter this material in school, on YouTube, and possibly in a lab. The more clearly you understand it, the better the conversations you can have.

Why Parents Should Know This

CRISPR-Cas9 was first described as a genome editing tool in a 2012 paper in Science by Jennifer Doudna and Emmanuelle Charpentier, work for which they received the 2020 Nobel Prize in Chemistry. In the decade since, it has moved from a laboratory curiosity to an FDA-approved medical therapy, with more than 50 clinical trials underway across a range of diseases.

This is not a technology your kid will only encounter in a biology textbook. High school students can design guide RNAs using free online tools. The iGEM (International Genetically Engineered Machine) competition — the world’s largest synthetic biology competition — has teams from over 40 countries, including high school divisions. Undergraduate research programs at major universities actively recruit students with genuine curiosity about molecular biology and willingness to learn laboratory technique.

Understanding CRISPR also means understanding a broader framework: how genes work, what it means to “edit” a living organism, and what categories of editing are considered scientifically acceptable versus ethically out of bounds. These distinctions matter for anyone who will vote on biotech policy, use genetic health services, or work anywhere in the life sciences.

How CRISPR-Cas9 Actually Works

Every cell in your body contains your complete genome — about 3 billion base pairs of DNA, organized into 23 pairs of chromosomes. Genes are specific sequences within that DNA that encode proteins. Mutations — changes in the sequence — can disrupt how a gene works. Some mutations cause disease. Sickle cell disease, for instance, is caused by a single-nucleotide mutation in the gene that encodes hemoglobin: one adenine replaced by thymine. That one-letter change causes the hemoglobin protein to misfold, deforming red blood cells and causing the cascade of effects that makes sickle cell disease so debilitating.

CRISPR-Cas9 is a molecular tool that can find a specific sequence in the genome and cut the DNA there. It has two components:

The guide RNA (gRNA): A short, synthetic RNA molecule designed to match the target DNA sequence. It acts as a GPS — it base-pairs with the complementary strand of DNA exactly where you want to cut.

The Cas9 protein: A bacterial enzyme that acts as molecular scissors. It binds to the guide RNA and then cuts both strands of the DNA at the targeted location.

Once both DNA strands are cut, the cell’s natural repair machinery takes over. There are two main repair pathways: one that rejoins the cut ends imprecisely (non-homologous end joining, or NHEJ — often used to disrupt a gene by causing a small deletion or insertion) and one that can incorporate a template sequence provided by the researcher (homology-directed repair, or HDR — used to correct a specific mutation or insert a new sequence).

This is the core mechanism. It is elegant because guide RNA design is straightforward and can be done computationally. Changing the target just means designing a new 20-nucleotide guide sequence. It is also, fundamentally, a modification of a bacterial immune system — bacteria use Cas9 to cut and destroy viral DNA when they are infected.

Beyond the Original Tool: Base Editing and Prime Editing

CRISPR-Cas9 cuts DNA, which carries risks — off-target cuts, unintended repair outcomes. Researchers have developed more precise approaches that don’t require cutting both strands.

Base editing, developed largely by David Liu’s lab at Harvard and the Broad Institute, uses a modified Cas9 that doesn’t cut DNA but can chemically convert one nucleotide into another. An adenine base editor, for example, can change A to G (technically A to inosine, which is read as G). This allows correction of single-letter mutations — like the one in sickle cell disease — without creating a double-strand break. Two papers in Nature in 2016 and 2017 established adenine and cytosine base editors as powerful tools with improved precision.

Prime editing, also from Liu’s lab (published in Nature in 2019), goes further. It can make all 12 possible point mutation corrections, as well as small insertions and deletions, without requiring double-strand breaks or a separate DNA template. Researchers have described it as a “find and replace” function for the genome, compared to base editing’s “search and overwrite” capability.

These distinctions matter practically: base editing and prime editing have lower rates of unintended edits at off-target sites, which is critical for clinical use.

The Key Distinction: Somatic vs. Germline Editing

This is the ethical fault line, and it’s the clearest explanation of why Casgevy is celebrated and He Jiankui is in prison.

Somatic cell editing modifies the cells of a living patient — blood cells, liver cells, immune cells. Changes affect only that patient. They cannot be passed on to children. The edited cells will eventually die; the patient’s germline (eggs or sperm) is unaffected. This is the category in which essentially all current CRISPR therapies operate. It is considered ethically analogous to any other medical treatment.

Germline editing modifies embryos, eggs, or sperm — cells that will develop into a complete organism and whose genetic changes will be inherited by every subsequent generation. He Jiankui edited embryos. Every cell of the resulting children carries his edits, and if those children have children, the edits continue. The scientific community’s objection is not primarily about intent (the goal of HIV resistance is not objectionable in itself) — it is about making permanent, heritable changes to the human genome without the safety evidence or ethical consensus to justify it, and without the ability to obtain consent from the people most affected: the children and all future generations.

A 2020 report from the National Academies of Sciences and the Royal Society concluded that heritable human genome editing should not proceed until there is “broad societal consensus” and far more safety data. No major scientific body has endorsed germline editing for clinical use.

Editing Type	What’s Modified	Heritable?	Examples	Ethical Status
Somatic cell (ex vivo)	Patient’s cells outside body	No	Casgevy (sickle cell), CAR-T therapies	FDA-regulated; clinical trials active
Somatic cell (in vivo)	Cells inside patient’s body	No	NTLA-2001 (transthyretin amyloidosis), CRISPR for Duchenne MD	Clinical trials ongoing
Base editing	Specific nucleotide in patient cells	No	BEAM-101 (sickle cell) in trials	Research and early clinical stage
Germline editing	Embryo or reproductive cells	Yes — all descendants	He Jiankui CCR5 edit (2018)	Broadly condemned; moratorium in most countries

FDA Approval of Casgevy: What It Actually Means

Casgevy (exagamglogene autotemcel, or exa-cel) was developed by Vertex Pharmaceuticals and CRISPR Therapeutics. The FDA approved it in December 2023 for sickle cell disease in patients 12 and older, and simultaneously approved it for transfusion-dependent beta-thalassemia.

The treatment process is intensive. Stem cells are extracted from the patient’s bone marrow. Those cells are then edited using CRISPR-Cas9 to reactivate fetal hemoglobin — a type of hemoglobin the body naturally produces before birth and then largely switches off. Fetal hemoglobin functions normally even in patients with the sickle cell mutation. Turning it back on largely corrects the disease. The edited cells are then infused back into the patient after the patient undergoes chemotherapy to clear existing bone marrow cells.

Clinical trial results were striking. In the trial reported in the New England Journal of Medicine in 2023, 29 of 29 patients with sickle cell disease who could be evaluated had no severe vaso-occlusive crises (the painful, dangerous episodes that define the disease experience) for at least 12 months after treatment. The follow-up period continues. The therapy does not yet have a lifetime cure label — we don’t know what 20 or 30 years of outcomes look like — but the near-term results are genuinely significant.

The cost of Casgevy is approximately $2.2 million per patient, which immediately raises questions of access, equity, and how the healthcare system handles curative one-time therapies. These are real and unresolved policy questions.

The iGEM Path for High Schoolers

The International Genetically Engineered Machine (iGEM) Foundation runs an annual competition where teams design and build genetic systems using standard biological parts. High school teams participate alongside undergraduate and graduate teams. Projects have ranged from engineering bacteria to detect heavy metals in water to developing biosensors for food safety to creating organisms that can break down plastic.

iGEM teams work in actual laboratories, present their results at a Giant Jamboree (typically in Paris), and are evaluated on scientific rigor, safety practices, and the quality of their documentation. The competition has produced publishable research and launched careers. If your teenager is serious about biology or bioengineering, iGEM is among the most substantive extracurricular programs available — comparable to a serious science fair but with a team structure and real laboratory access.

For younger students, the Cold Spring Harbor Laboratory’s DNA Learning Center has free online courses in molecular biology and CRISPR, designed for non-specialists. These are genuinely good science, not glossy explainers.

What This Means for Your Kid’s Future

The career pathways in genetic engineering are broad and growing. The Bureau of Labor Statistics projects faster-than-average job growth for biomedical engineers and medical scientists through 2032. The gene therapy sector alone had more than 1,000 active clinical trials globally as of 2023, according to the Alliance for Regenerative Medicine.

Molecular biologist, genetic counselor, biomedical engineer, regulatory affairs specialist for biologics, bioinformatics scientist, CRISPR patent attorney — all of these careers are directly adjacent to the technology this article describes. The cross-disciplinary skills (biology + computation + ethics + communication) that the field requires are exactly the skills a thoughtful science education is building toward. The connection between understanding how synthetic biology and genetic engineering converge is worth exploring as your kid’s interests develop.

What Parents Should Do

Start with the molecule, not the controversy

Before discussing He Jiankui or gene-edited babies, make sure your kid understands the basic mechanism: DNA has a sequence, guide RNA finds a specific location in that sequence, Cas9 cuts there. Even a middle schooler can grasp this with a good analogy — the guide RNA is like a search term in a word processor, and Cas9 is like the delete key. Build the mental model first; the ethical discussion lands better when there’s a real foundation.

Look at the Casgevy approval news together

The FDA’s press release on Casgevy (publicly accessible on fda.gov) is written to be readable by non-specialists. Reading it with your teenager — what disease does it treat, how was it tested, what does “approved” actually mean — is a practical exercise in scientific literacy. It’s also a piece of genuinely good news to share.

Have the He Jiankui conversation explicitly

This story is one of the most important ethics case studies in modern science, and it’s approachable. What did he do? Why did the scientific community object? What would have needed to be true for the experiment to be defensible? This is a real conversation with real substance, and teenagers find it genuinely interesting. It also establishes the somatic/germline distinction in a memorable way.

Find the iGEM high school teams near you

The iGEM website (igem.org) lists past and current teams by location. Many are affiliated with universities or research institutions and are open to new members. Even attending an iGEM competition presentation — often open to the public — gives a teenager concrete exposure to what serious high school biology research looks like.

Use 23andMe or AncestryDNA as a gateway conversation

If your family has used consumer genomics, it’s a concrete hook: what does the test actually sequence? What kinds of variants does it report? What does it not look at? Consumer genomics is not CRISPR, but it introduces the concept that genetic information has structure, that some variants have consequences, and that there are legitimate questions about who has access to that data.

Connect to the broader ethics of emerging science

The CRISPR story — tool discovered in 2012, first therapy approved 2023, ethical scandal in 2018 — illustrates a pattern: powerful tools arrive before the ethical consensus about how to use them. Teaching your kid to notice this pattern, and to ask who benefits, who bears the risk, and who decides, is a transferable skill across every emerging technology they’ll encounter.

Frequently Asked Questions

Is CRISPR the same as GMO food?

Both involve modifying DNA, but the methods are different. Traditional GMOs often involve inserting genes from another species using bacterial vectors (Agrobacterium is commonly used in plant engineering). CRISPR typically makes targeted edits to the organism’s existing genome — deleting, correcting, or inserting small sequences — without necessarily introducing foreign genes. The regulatory category and public perception are complicated; the underlying biology is distinct.

Could someone use CRISPR to edit my child’s genes without consent?

Not in any realistic scenario. CRISPR-based somatic therapies require extracting a significant amount of tissue (typically bone marrow stem cells), processing those cells outside the body for days to weeks, and then reinfusing them after intensive medical preparation. It is not something that can be done covertly or without the patient’s active participation in a hospital setting. Germline editing of embryos is technically possible in an IVF context but is illegal or heavily regulated in virtually every jurisdiction.

How accurate is CRISPR? Can it edit the wrong gene?

Off-target editing — cuts at unintended locations in the genome — is a real concern that has been the focus of significant research. Modern tools (including base editing and prime editing) have substantially improved specificity compared to the original CRISPR-Cas9 system. Clinical applications use extensive screening to verify on-target editing and detect off-target events before returning cells to a patient. It is not perfectly precise, and improving that precision remains active research.

What diseases might CRISPR cure in the next decade?

Active clinical trials target sickle cell disease (already approved), beta-thalassemia (already approved), transthyretin amyloidosis (early data is promising), Duchenne muscular dystrophy, acute myeloid leukemia, several forms of inherited blindness, and high cholesterol via PCSK9 editing. The Alliance for Regenerative Medicine tracks these trials publicly. Timeline from trial to approval is typically 5–10 years if results are strong.

Is a career in genetic engineering financially viable?

Median salaries for molecular biologists and biomedical engineers are in the $80,000–$130,000 range, with research scientists at biotech companies and academic labs at the higher end. The Bureau of Labor Statistics projects 10% job growth for medical scientists through 2032, faster than average. The gene therapy sector is expanding rapidly, and regulatory, clinical, and commercialization roles are as important as laboratory positions.

---

About the author

Ricky Flores is the founder of HiWave Makers and an electrical engineer with 15+ years developing consumer technology at Apple, Samsung, and Texas Instruments. He writes about how kids learn to build, think, and create in a tech-saturated world. Read more at hiwavemakers.com.

---

Sources

1. Doudna, J. A., & Charpentier, E. (2012). “A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity.” Science, 337(6096), 816–821. https://doi.org/10.1126/science.1225829

2. Frangoul, H., et al. (2021). “CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia.” New England Journal of Medicine, 384(3), 252–260. https://doi.org/10.1056/NEJMoa2031054

3. Gaudelli, N. M., et al. (2017). “Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage.” Nature, 551, 464–471. https://doi.org/10.1038/nature24644

4. Anzalone, A. V., et al. (2019). “Search-and-replace genome editing without double-strand breaks or donor DNA.” Nature, 576, 149–157. https://doi.org/10.1038/s41586-019-1711-4

5. U.S. Food and Drug Administration. (2023). FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease

6. National Academies of Sciences, Engineering, and Medicine. (2020). Heritable Human Genome Editing. The National Academies Press. https://doi.org/10.17226/25665

7. Alliance for Regenerative Medicine. (2023). Annual Report on Gene, Cell, and RNA Therapy. https://alliancerm.org/publication/arm-annual-report/

8. Bureau of Labor Statistics, U.S. Department of Labor. (2023). Occupational Outlook Handbook: Biomedical Engineers. https://www.bls.gov/ooh/architecture-and-engineering/biomedical-engineers.htm